Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.
Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List Within 30...
ATCC Announces $87 Million Award for Project NextGen for Vaccines, from Barda.
ATCC, the world’s premier biological materials management and standards organization, today announced a five-year, $87 million award from the Biomedical Advanced Research and Development...
Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the week and then AFTER speaking to CEO David Dodd and the Head...
Bridging the Immunity Gap: An In-Depth Conversation with GeoVax’s (GOVX) CEO, David Dodd
In an era of rapid scientific development, the pharmaceutical industry constantly evolves to meet new challenges and seize emerging opportunities. GeoVax, a biotechnology company...
We Warned About VERU (VERU) $2.50, Down 89%.
Down 35% Today, and 89% from $24, and a $1.9 Billion Market Cap, Only 7 Months ago.
The FDA says we have some nice parting...
Provention Biosciences (PRVB) Enters the Danger Zone.
Chart Looks Beautiful - But Nervous is why, we use soft and dry.
LIVE QUOTE
We'll be short and sweet. We make no prediction as for...
VERU (VERU) $6.66, Goes Poof.
Veru Provides Update on FDA Advisory Committee Meeting
Market Cap Plunges from $1.9 Billion to $540 Million.
"In the long history of drug trials for patients...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that the amended protocol is still under...
Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
To say Eric Sprott has left a legendary mark on the world of mining investment would be an understatement. With a career spanning five...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
